Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 36353 results found since Jan 2013.
Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor
The aims of this study were to correlate residual mammographic microcalcifications after neoadjuvant chemotherapy (NAC) with pathological results and to compare the accuracy of mammography (MG) and magnetic re...
Source: World Journal of Surgical Oncology - November 6, 2017 Category: Cancer & Oncology Authors: Yeong Yi An, Sung Hun Kim and Bong Joo Kang Tags: Research Source Type: research
Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
Approximately half of patients who undergo radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) will succumb to metastatic disease. We summarize the evidence for neoadjuvant radiation (NAR), chemo (NAC), and immunotherapy (checkpoint inhibition) prior to RC for MIBC.
Source: Urologic Oncology: Seminars and Original Investigations - November 8, 2017 Category: Urology & Nephrology Authors: Tom J.N. Hermans, Charlotte S. Voskuilen, Michiel S. van der Heijden,, Bernd J. Schmitz-Dr äger, Wassim Kassouf, Roland Seiler, Ashish M. Kamat, Petros Grivas, Anne E. Kiltie, Peter C. Black, Bas W.G. van Rhijn Tags: Seminars article Source Type: research
Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy
An adequate pelvic lymph node dissection (LND) during radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has been shown to provide a survival benefit. We designed a study to assess the effect of adequate LND on overall survival (OS) according to cT stage and receipt of neoadjuvant chemotherapy (NAC).
Source: Urologic Oncology: Seminars and Original Investigations - November 20, 2017 Category: Urology & Nephrology Authors: Nicolas von Landenberg, Jacqueline M. Speed, Alexander P. Cole, Thomas Seisen, Stuart R. Lipsitz, Philipp Gild, Mani Menon, Adam S. Kibel, Florian Roghmann, Joachim Noldus, Maxine Sun, Quoc-Dien Trinh Tags: Original article Source Type: research
Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations
Squamous cell carcinoma and adenocarcinoma represent approximately 98% of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, squamous cell carcinoma continues to be the predominant histologic type. Integrated positron emission tomography or computed tomography with 2-[fluorine18] fluro-2-deoxy-d-glucose is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of res...
Source: Seminars in Ultrasound CT and MRI - August 8, 2017 Category: Radiology Authors: Sonia L. Betancourt Cuellar, Diana P. Palacio, Marcelo F. Benveniste, Brett W. Carter, Wayne L. Hofstetter, Edith M. Marom Source Type: research
Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis
With limited sample sizes and single-institution designs, how complete response (CR) after neoadjuvant chemotherapy (NAC) influences breast conserving surgery (BCS) and its value in prognosis are not clear.
Source: World Journal of Surgical Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Xuan Li, Danian Dai, Bo Chen, Hailin Tang and Weidong Wei Tags: Research Source Type: research
Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma
To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC.
Source: Journal of Vascular and Interventional Radiology : JVIR - December 5, 2017 Category: Radiology Authors: Peiman Habibollahi, Sara P. Shamchi, Rashmi Tondon, Brett L. Ecker, Terence P. Gade, Stephen Hunt, Michael C. Soulen, Emma E. Furth, Matthew H. Levine, Gregory Nadolski Tags: Clinical Study Source Type: research
Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial
Standard treatment for locally advanced rectal cancer includes 5 –6 weeks of neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision 6–8 weeks later. NACRT improves local disease control and...
Source: Trials - January 12, 2018 Category: General Medicine Authors: Andria R. Morielli, Nawaid Usmani, Normand G. Boul é, Diane Severin, Keith Tankel, Tirath Nijjar, Kurian Joseph, Alysa Fairchild and Kerry S. Courneya Tags: Study protocol Source Type: research
Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy
Vaccination of mice with tumors treated with Doxorubicin promotes a T cell immunity that relies on dendritic cell (DC) activation and is responsible for tumor control in vaccinated animals. Despite Doxorubicin...
Source: BMC Cancer - January 15, 2018 Category: Cancer & Oncology Authors: David A. Bernal-Est évez, Oscar García, Ramiro Sánchez and Carlos A. Parra-López Tags: Research article Source Type: research
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
Source: Cancer Management and Research - January 15, 2018 Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma
Head and neck cancers are the commonest cancer in Southeast Asia. Despite being a surface cancer, it is associated with significant morbidity as despite early detection by the patients they often report for tr...
Source: World Journal of Surgical Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Manoj Pandey, Krishna Kiran Kannepali, Ruhi Dixit and Mohan Kumar Tags: Research Source Type: research
Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC
The tumour microenvironment consists of malignant cells, stroma and immune cells. In women with large and locally advanced breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC), tumour-infiltrating...
Source: BMC Cancer - February 2, 2018 Category: Cancer & Oncology Authors: Viriya Kaewkangsadan, Chandan Verma, Jennifer M. Eremin, Gerard Cowley, Mohammad Ilyas and Oleg Eremin Tags: Research article Source Type: research
Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer
Source: OncoTargets and Therapy - February 1, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands
Primary debulking surgery (PDS) followed by adjuvant chemotherapy is historically recommended as first line treatment for advanced stage ovarian cancer. Two randomized controlled trials, however, showed similar efficacy and reduced toxicity with neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Nevertheless, uptake of NACT-IDS varies widely between hospitals, which cannot be explained by difference in patient populations. In this survey, we therefore aimed to evaluate the views on NACT-IDS among all Dutch gynaecologists and medical oncologists involved in the treatment of ovarian cancer.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - February 28, 2018 Category: OBGYN Authors: M. Timmermans, G.S. Sonke, W.J. van Driel, R.I. Lalisang, P.B. Ottevanger, C.D. de Kroon, K.K. Van de Vijver, M.A. van der Aa, R.F. Kruitwagen Tags: Full length article Source Type: research
Peripheral inflammation/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy
Source: OncoTargets and Therapy - March 15, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center
The association of preoperative systemic and intraperitoneal chemotherapy has been described in Eastern patients with very good outcomes in treatment responders. The aim of this paper is to describe the initia...
Source: World Journal of Surgical Oncology - March 22, 2018 Category: Cancer & Oncology Authors: Bianca Escorel Costa Fava, Wilson Luiz da Costa Jr, Maria Luiza L. Medeiros, Marina Sonagli, H éber Salvador de Castro Ribeiro, Alessandro L. Diniz, André L. Godoy, Igor C. de Farias, Victor Hugo Fonseca de Jesus, Maria Dirlei F. S. Begnami and Felipe J Tags: Case Report Source Type: research
